Skip to main content

Advertisement

SpringerLink
Log in

Prostate cancer pain management: EAU guidelines on pain management

  • EAU Guideline
  • Published:
World Journal of Urology Aims and scope Submit manuscript

Abstract

Context

The first publication of the European Association of Urology (EAU) guidelines on Pain Management in Urology dates back to 2003. Since then, these guidelines have been revised several times with the most recent update achieved in 2010.

Objective

Given the scope of the full text guidelines, condensing the entire document was no option in this context. This paper presents a summary of the section of pain management in prostate cancer, a topic considered of direct relevance for the practicing urologist.

Evidence acquisition

A multidisciplinary expert panel (urologists, anaesthesiologists, radio-oncologists) compiled this document based on a comprehensive consultation of the literature. Data were identified through a structured search, covering the time frame 2000 through 2010, using Medline and Embase as well as the Cochrane Library of systematic reviews. The scientific papers were weighed by the expert panel and a level of evidence (LE) assigned. Recommendations have been graded as a means to provide transparency between the underlying evidence and the guidance provided.

Evidence summary

Pain can occur in each stage of prostate cancer. It could be caused by the cancer itself (77%), be related to the cancer treatment (19%) or be unrelated to either (3%). The incidence of pain rises to 90% as patients enter the terminal phase of their illness. The physician’s task is to discover and treat the cause of pain and the pain itself, to determine whether or not the underlying cause is treatable, to provide pain relief and palliative care. These tasks more often than not require a multidisciplinary team. Pain management involves mainly pharmacotherapy, including direct anticancer therapy such as androgen deprivation and chemotherapy, as well as analgetics, for instance non-steroidal anti-inflammatory drugs (NSAIDs) or opioids. In case of local impairment due to the cancer or its metastases, primary treatments like surgery, radiotherapy or radionuclides can provide adequate pain relief. In addition, in palliative care, functional, psychosocial and spiritual support are essential components. The EAU guidelines on Pain Management in Urology are available in a number of different formats through the EAU Central Office and the EAU website (http://www.uroweb.org/guidelines/online-guidelines/).

Conclusion

The mainstay of pain management in prostate cancer is involvement of and collaboration between experts from a number of disciplines to be able to achieve a complete pain evaluation and to offer the full range of treatment options. Prostate cancer–related pain can, in most cases, be managed effectively, but it requires careful monitoring where a balance should be found between pain relief and potential side effects of treatment and quality of life (QoL).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Oxford Centre for Evidence-Based Medicine Levels of Evidence (2001) Produced by Bob Phillips, Chris Ball, Dave Sackett, Doug Badenoch, Sharon Straus, Brian Haynes, Martin Dawes since November 1998. Updated by Jeremy Howick, March 2009. Centre for Evidence Based Medicine Web site. http://www.cebm.net/index.aspx?o=5653. Accessed Apr 2011.

  2. Foley KM (1979) Pain syndromes in patients with cancer. In: Bonica JJ, Ventafridda V (eds) Advances in pain research and therapy 2. Raven Press, New York, pp 59–75

    Google Scholar 

  3. Twycross RG, Lack SA (1983) Symptom control in far advanced cancer: pain relief. Pitman, London, p 6

    Google Scholar 

  4. Jensen MP (2003) The validity and reliability of pain measures in adults with cancer. J Pain 4(1):2–21

    Article  PubMed  Google Scholar 

  5. Rosier EM, Iadarola MJ, Coghill RC (2002) Reproducibility of pain measurement and pain perception. Pain 98(1–2):205–216

    Article  PubMed  Google Scholar 

  6. Melzack R (1975) The McGill pain questionnaire: major properties and scoring methods. Pain 1:277–299

    Article  PubMed  CAS  Google Scholar 

  7. Mercadante S (1997) Malignant bone pain: pathophysiology and treatment. Pain 69(1–2):1–18

    Article  PubMed  CAS  Google Scholar 

  8. Zech DF, Grond S, Lynch J, Hertel D, Lehmann KA (1995) Validation of the world health organization guidelines for cancer pain relief: a 10-year prospective study. Pain 63:65–76

    Article  PubMed  CAS  Google Scholar 

  9. Caraceni A, Portenoy RK (1999) An international survey of cancer pain, characteristics and syndromes. Pain 82:263–274

    Article  PubMed  CAS  Google Scholar 

  10. Treede RD, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW, Hansson P, Hughes R, Nurmikko T, Serra J (2008) Neuropathic pian. Redefinition and a grading system for clinical and research purposes. Neurology 70:1630–1635

    Article  PubMed  CAS  Google Scholar 

  11. Rasmussen PV, Sindrup SH, Jensen TS, Bach FW (2004) Symptoms and signs in patients with suspected neuropathic pain. Pain 110:461–469

    Article  PubMed  Google Scholar 

  12. Kamat AM, Huang SF, Bermejo CE, Rosser CJ, Pettaway CA, Pisters PW, Guitreau DP, Pisters LL (2003) Total pelvic exenteration: effective palliation of perineal pain in patients with locally recurrent prostate cancer. J Urol 170(5):1868–1871

    Article  PubMed  Google Scholar 

  13. Wilson JR, Urwin GH, Stower MJ (2005) The role of percutaneous nephrostomy in malignant ureteric obstruction. Ann R Coll Surg Engl 87(1):21–24

    Article  PubMed  CAS  Google Scholar 

  14. Thompson JC, Wood J, Feuer D (2007) Prostate cancer: palliative care and pain relief. Br Med Bull 83:341–354

    Article  PubMed  CAS  Google Scholar 

  15. Ok JH, Meyers FJ, Evans CP (2005) Medical and surgical palliative care of patients with urological malignancies. J Urol 174:1177–1182

    Article  PubMed  Google Scholar 

  16. Russo P (2000) Urologic emergencies in the cancer patient. Semin Oncol 27(3):284–298

    PubMed  CAS  Google Scholar 

  17. Schröder FH, Whelan P, de Reijke TM, Kurth KH, Pavone-Macaluso M, Mattelaer J, van Velthoven RF, Debois M (2004) Members of the EORTC Genito-Urinary Group Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the “European Organization for Research and Treatment of Cancer” (EORTC) Protocol 30892. Eur Urol 45(4):457–464

    Article  PubMed  Google Scholar 

  18. McQuay HJ, Collins SL, Carroll D (2000) Radiotherapy for the palliation of painful bone metastases. Cochrane Database Sys Rev 2:CD001793

    Google Scholar 

  19. Wu J, Wong R, Johnston M et al (2003) Meta-analysis of dose-fractionation radiotherapy trials for the palliation of painful bone metastases. Int J Radiot Oncol Biol Physiol 55:594–605

    Article  Google Scholar 

  20. Sze WM, Shelley M, Held I et al (2004) Palliation of metastatic bone pain: single fraction versus multifraction radiotherapy. Cochrane Database Syst Rev 2:CD004721

    Google Scholar 

  21. George R, Jeba J, Ramkumar G et al (2008) Interventions for the treatment of metastatic extradural spinal cord compression in adults. Cochrane Database Syst Rev 8(4):CD006716

    Google Scholar 

  22. Klimo P, Thompson CJ, Kestle JRW et al (2005) A meta-analysis of surgery versus conventional radiotherapy for the treatment of metastatic spinal epidural disease. Neuro Oncol 7:64–76

    Article  PubMed  Google Scholar 

  23. Paes FM, Serafini AN (2010) Systemic metabolic radiopharmaceutical therapy in the treatment of metastatic bone pain. Semin Nucl Med 40:89–104

    Article  PubMed  Google Scholar 

  24. Krishnamurthy GT, Krishnamurthy S (2000) Radionuclides for metastatic bone pain palliation: a need for rational re-evaluation in the new millennium. J Nucl Med 41(4):688–691

    PubMed  CAS  Google Scholar 

  25. Finlay IG, Mason MD, Shelley M (2005) Radioisotopes for the palliation of metastatic bone cancer: a systematic review. Lancet Oncol 6:392–400

    Article  PubMed  CAS  Google Scholar 

  26. Resche I, Chatal JF, Pecking A, Ell P, Duchesne G, Rubens R, Fogelman I, Houston S, Fauser A, Fischer M, Wilkins D (1997) A dose-controlled study of 153Sm- ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases. Eur J Cancer 33:1583–1591

    Article  PubMed  CAS  Google Scholar 

  27. Bodei L, Lam M, Chiesa C, Flux G, Brans B, Chiti A (2008) Giammarile. European Association of Nuclear medicine (EANM): EANM procedure guidelines for treatment of refractory metastatic bone pain. Eur J Nucl Med Mol Imaging 35(10):1934–1940

    Article  PubMed  Google Scholar 

  28. Saad H, Higano C, Sartor O, Colombel M, Murray R, Mason MD, Tubaro A, Schulman C (2006) The role of bisphosphonates in the treatment of prostate cancer: recommendations from an expert panel. Clin Genitourin Cancer 4(4):257–262

    Article  PubMed  CAS  Google Scholar 

  29. Smith MR (2005) Zoledronic acid to prevent skeletal complications in cancer: corroborating the evidence. Cancer Treat Rev 31(Suppl.3):19–25

    Google Scholar 

  30. Michaelson MD, Smith MR (2005) Bisphosphonates for treatment and prevention of bone metastases. J Clin Oncol 23(32):8219–8224

    Article  PubMed  CAS  Google Scholar 

  31. Shih A, Jackson KC, II (2007) Role of corticosteroids in palliative care. J Pain Palliat Care Pharmacother 21(4):69–76

  32. Berthold DR, Pond GR, Roessner M, de Wit R, Eisenberger M (2008) TAX-327 investigators. Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study. Clin Cancer Res 14(9):2763–2767

    Article  PubMed  CAS  Google Scholar 

  33. World Health Organization (1990) Cancer pain relief and palliative Care. Report of a WHO expert committee. World Health Organization Technical Report Series, 804. Geneva, Switzerland: World Health Organization

  34. Grond S, Zech D, Schug SA, Lynch J, Lehman KA (1991) Validation of the world health organization guidelines for cancer pain relief during the last days and hours of life. J Pain Symptom Manage 6(7):411–422

    Article  PubMed  CAS  Google Scholar 

  35. Maltoni M, Scarpi E, Modonesi C et al (2005) A validation study of the WHO analgesic ladder: a two-step vs three-step strategy. Supp Care Cancer 13:888–894

    Article  Google Scholar 

  36. Miguel R (2000) Interventional treatment of cancer pain: the fourth step in the World Health Organization analgesic ladder? Cancer Control 7:149–156

    Google Scholar 

  37. Vranken JH (2003) The palliative treatment with catheter techniques of intractable cancer pain: fourth step in the World Health Organization analgesic ladder. In: Recent Research development in Anesthesia & Analgesia. Transworld Research Network, Kerala, pp 59–71

  38. Drew J, Stambaugh JE Jr (1988) The combination of ibuprofen and oxycodone/acetaminophen in the management of chronic cancer pain. Clin Pharmacol Ther 44(6):665–669

    Article  PubMed  Google Scholar 

  39. Fitzgerald GA (2002) Cardiovascular pharmacology of nonselective nonsteroidal anti-inflammatory drugs and coxibs: clinical considerations. Am J Cardiol 89(6A):26D–32D

    Google Scholar 

  40. Schug SA, Sidebotham DA, Mc Guinnety M, Thomas J, Fox L (1998) Acetaminophen as an adjunct to morphine by patient-controlled analgesia in the management of acute postoperative pain. Anesth Analg 87(2):368–372

    PubMed  CAS  Google Scholar 

  41. Stamer UM, Stüber F (2007) Genetic factors in pain and its treatment. Curr Opin Anaesthesiol 20(5):478–484

    Article  PubMed  Google Scholar 

  42. Hanning CD (1990) The rectal absorption of opioids. In: Benedetti C, Chapman C R, Giron G (eds) Opioid analgesia. Advances in pain research and therapy, vol 14. Raven Press, New York, pp 259–269

  43. Clark AJ, Ahmedzai SH, Allan LG, Camacho F, Horbay GL, Richarz U, Simpson K (2004) Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer pain. Curr Med Res Opin 20(9):1419–1428

    Article  PubMed  CAS  Google Scholar 

  44. Ahmedzai S, Brooks D (1997) Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. J Pain Symptom Manage 13(5):254–261

    Article  PubMed  CAS  Google Scholar 

  45. Coluzzi PH, Schwartzberg L, Conroy JD, Charapata S, Gay M, Busch MA, Chavez J, Ashley J, Lebo D, McCracken M, Portenoy RK (2001) Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). Pain 91(1–2):123–130

    Article  PubMed  CAS  Google Scholar 

  46. Saarto T, Wiffen PJ (2007) Antidepressants for neuropathic pain. Cochrane Database Syst Rev 4:CD005454

    Google Scholar 

  47. Greenberg DB (1991) Strategic use of benzodiazepines in cancer patients. Oncology (Williston Park). 5(4):83–88; discussion 88, 90, 95.

  48. Caraceni A, Zecca E, Bonezzi C et al (2004) Gabapentin for neuropathic cancer pain: a randomized controlled trial from the gabapentin cancer pain study group. J Clin Oncol 22:2909–2917

    Article  PubMed  CAS  Google Scholar 

  49. Bell R, Eccleston C, Kalso E (2003) Ketamine as an adjuvant to opioids for cancer pain. Cochrane Database Syst Rev 1:CD003351

  50. Douglas I, Bush D (1999) The use of patient-controlled boluses of local anaesthetic via a psoas sheath catheter in the management of malignant pain. Pain 82:105–107

    Article  PubMed  CAS  Google Scholar 

  51. Vranken JH, van der Vegt MH, Ubags LH, Pijl AJ, Dzoljic M (2002) Continuous sacral nerve root block in the management of neuropathic cancer pain. Anesth Analg 95:1724–1725

    Article  PubMed  Google Scholar 

  52. van Dongen RT, Crul BJ, de Bock M (1993) Long-term intrathecal infusion of morphine/bupivacaine mixtures in the treatment of cancer pain: a retrospective analysis of 51 cases. Pain 55:119–123

    Article  PubMed  Google Scholar 

  53. van Dongen RTM, van Ee R, Crul BJP (1997) Neurologic impairment during long-term intrathecal infusion of bupivacaine in cancer patients; a sign of spinal cord compression. Pain 69:205–209

    Article  PubMed  Google Scholar 

  54. Plancarte R, de Leon Casasola OA, El Helaly M, Allende S, Lema MJ (1997) Neurolythic superior hypogastric plexus block for chronic pelvic pain associated with cancer. Reg Anesth 22(6):562–568

    Google Scholar 

  55. Saunders C (1987) The philosophy of terminal cancer care. Ann Acad Med Singapore 16(1):151–154

    PubMed  CAS  Google Scholar 

  56. Nanton V, Docherty A, Meystre C, Dale J (2009) Finding a pathway: information and uncertainty along the prostate cancer patient journey. Br J Health Psychol 14:437–458

    Article  PubMed  CAS  Google Scholar 

  57. Thaxton L, Emshoff JG, Guessous O (2005) Prostate cancer support groups: a literature review. J Psychosoc Oncol 23(1):25–40

    Article  PubMed  Google Scholar 

  58. Velthuis MJ, Agasi-Idenburg SC, Aufdemkampe G, Wittink HM (2010) The effect of physical exercise on cancer-related fatigue during cancer treatment: a meta-analysis of randomised controlled trials. Clin Oncol (R Coll Radiol) 22(3):208–221

    Article  CAS  Google Scholar 

  59. Segal RJ, Reid RD, Courneya KS, Malone SC, Parliament MB, Scott SG, Venner PM, Quinney HA, Jones LW, Slovinec D’Angelo ME, Wellset GA (2003) Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. J Clin Oncol 21:1653–1659

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflict of interest in relation to the content of the manuscript. They have all contributed equally to the writing of this document.

Author information

Authors and Affiliations

  1. Department of Urology, Städtisches Klinikum Karlsruhe, Moltkestrasse 90, 76133, Karlsruhe, Germany

    Pia Bader

  2. Department of Urology, Staedtische Kliniken Moenchengladbach GmbH, Munich, Germany

    Dieter Echtle

  3. Department of Radiotherapy, Ghent University Hospital, Ghent, Belgium

    Valerie Fonteyne & Gert De Meerleer

  4. 2nd Department of Urology, Athens Medical School Sismanoglio Hospital, Athens, Greece

    Kostas Livadas

  5. Department of Urology, Hospital Universitario De Fuenlabrada, Fuenlabrada, Spain

    Alvaro Paez Borda

  6. Department of Anesthesiology, University of Athens Medical School “Laiko” Hospital, Athens, Greece

    Eleni G. Papaioannou

  7. Department of Anaesthesiology, Medisch Centrum Alkmaar, Alkmaar, The Netherlands

    Jan H. Vranken

  8. Department of Radiotherapy, Universitair Ziekenhuis Gent, Ghent, Belgium

    Gert De Meerleer

Authors
  1. Pia Bader
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dieter Echtle
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Valerie Fonteyne
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kostas Livadas
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Gert De Meerleer
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Alvaro Paez Borda
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Eleni G. Papaioannou
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jan H. Vranken
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pia Bader.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bader, P., Echtle, D., Fonteyne, V. et al. Prostate cancer pain management: EAU guidelines on pain management. World J Urol 30, 677–686 (2012). https://doi.org/10.1007/s00345-012-0825-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-012-0825-1

Keywords

Search

Navigation